Aurobindo Pharma Ltd (AUROPHARMA) - Financial and Strategic SWOT Analysis Review
Description
Aurobindo Pharma Ltd (AUROPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Aurobindo Pharma Ltd (Aurobindo) is a vertically integrated pharmaceutical company. Its primary activities include the development, manufacturing, and commercialization of pharmaceutical products. The company’s product portfolio includes injectables, API, and complex offerings, including biosimilars, vaccines, peptides, and metered dose inhalers. The company's products are used in various therapeutic segments such as neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and antibiotics. Aurobindo Pharma serves a global customer base, including multinational companies, and caters to their formulation manufacturing needs. The company operates through a network of alliances and partnerships across the globe. It operates manufacturing facilities in India, Brazil, Portugal, and the US; and R&D facilities in India and the US. Aurobindo is headquartered in Hyderabad, Telangana, India.
Aurobindo Pharma Ltd Key Recent Developments
Oct 01,2025: Aurobindo Pharma : Changes in Senior Management Personnel of the Company
Sep 05,2025: Completion of US FDA Inspection at Unit-XII of Aurobindo Pharma
Aug 12,2025: Aurobindo Pharma: Intimation of 38th Annual General Meeting
Aug 04,2025: Aurobindo Pharma Announces Financial Results for Quarter Ended June 30, 2025
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Aurobindo Pharma Ltd (Aurobindo) is a vertically integrated pharmaceutical company. Its primary activities include the development, manufacturing, and commercialization of pharmaceutical products. The company’s product portfolio includes injectables, API, and complex offerings, including biosimilars, vaccines, peptides, and metered dose inhalers. The company's products are used in various therapeutic segments such as neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and antibiotics. Aurobindo Pharma serves a global customer base, including multinational companies, and caters to their formulation manufacturing needs. The company operates through a network of alliances and partnerships across the globe. It operates manufacturing facilities in India, Brazil, Portugal, and the US; and R&D facilities in India and the US. Aurobindo is headquartered in Hyderabad, Telangana, India.
Aurobindo Pharma Ltd Key Recent Developments
Oct 01,2025: Aurobindo Pharma : Changes in Senior Management Personnel of the Company
Sep 05,2025: Completion of US FDA Inspection at Unit-XII of Aurobindo Pharma
Aug 12,2025: Aurobindo Pharma: Intimation of 38th Annual General Meeting
Aug 04,2025: Aurobindo Pharma Announces Financial Results for Quarter Ended June 30, 2025
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
64 Pages
- Section 1 - About the Company
- Aurobindo Pharma Ltd - Key Facts
- Aurobindo Pharma Ltd - Key Employees
- Aurobindo Pharma Ltd - Key Employee Biographies
- Aurobindo Pharma Ltd - Major Products and Services
- Aurobindo Pharma Ltd - History
- Aurobindo Pharma Ltd - Company Statement
- Aurobindo Pharma Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Section 2 – Company Analysis
- Company Overview
- Aurobindo Pharma Ltd - Business Description
- Business Segment: API Business
- Overview
- Performance
- Business Segment: ARV Formulations
- Overview
- Performance
- Business Segment: EU Formulations
- Overview
- Performance
- Business Segment: Growth Markets Formulations
- Overview
- Performance
- Business Segment: US Formulations
- Overview
- Performance
- Key Stats
- Geographical Segment: Europe
- Performance
- Geographical Segment: India
- Performance
- Geographical Segment: Rest of the World
- Performance
- Geographical Segment: USA
- Performance
- R&D Overview
- Aurobindo Pharma Ltd - Corporate Strategy
- Aurobindo Pharma Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Aurobindo Pharma Ltd - Strengths
- Aurobindo Pharma Ltd - Weaknesses
- Aurobindo Pharma Ltd - Opportunities
- Aurobindo Pharma Ltd - Threats
- Aurobindo Pharma Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
- Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Aurobindo Pharma Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Oct 01, 2025: Aurobindo Pharma : Changes in Senior Management Personnel of the Company
- Sep 05, 2025: Completion of US FDA Inspection at Unit-XII of Aurobindo Pharma
- Aug 12, 2025: Aurobindo Pharma: Intimation of 38th Annual General Meeting
- Aug 04, 2025: Aurobindo Pharma Announces Financial Results for Quarter Ended June 30, 2025
- Jun 29, 2025: AUROBINDO : Restart of Penicillin-G Production at our Kakinada Facility Post Receipt of ‘Consent to Operate’ from Andhra Pradesh Pollution Control Board
- May 26, 2025: Aurobindo Pharma Announces Financial Results for Quarter Ended March 31, 2025
- Apr 11, 2025: Aurobindo Pharma : Completion of US FDA Inspection at Raleigh Plant, North Carolina, Owned by Aurolife Pharma
- Apr 11, 2025: Aurobindo Pharma : Completion Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma, A Wholly Owned Step-Down Subsidiary Of The Company
- Feb 20, 2025: Classification of US FDA Inspection at one of the Warehouses of Aurobindo Pharma USA a 100% Subsidiary of the Company
- Feb 18, 2025: Aurobindo Completion of US FDA Pre-Approval Inspection (PAI) at Eugia Steriles, a 100% stepdown subsidiary of the Company
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Aurobindo Pharma Ltd, Key Facts
- Aurobindo Pharma Ltd, Key Employees
- Aurobindo Pharma Ltd, Key Employee Biographies
- Aurobindo Pharma Ltd, Major Products and Services
- Aurobindo Pharma Ltd, History
- Aurobindo Pharma Ltd, Other Locations
- Aurobindo Pharma Ltd, Subsidiaries
- Aurobindo Pharma Ltd, Joint Venture
- Aurobindo Pharma Ltd, Key Competitors
- Aurobindo Pharma Ltd, Ratios based on current share price
- Aurobindo Pharma Ltd, Annual Ratios
- Aurobindo Pharma Ltd, Annual Ratios (Cont...1)
- Aurobindo Pharma Ltd, Annual Ratios (Cont...2)
- Aurobindo Pharma Ltd, Interim Ratios
- Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Aurobindo Pharma Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Aurobindo Pharma Ltd, Performance Chart (2021 - 2025)
- Aurobindo Pharma Ltd, Ratio Charts
- Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Aurobindo Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
